{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"42.3","upperLimit":"79.3","value":"62.1"}]}],"title":"Confirmed objective response rate"},{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"72.6","upperLimit":"97.8","value":"89.7"}]}],"title":"Confirmed disease control rate"}],"denoms":[{"counts":[{"groupId":"OG000","value":"29"}],"units":"Participants"}],"description":"To retrospectively assess anti-tumor activity of sunvozertinib in treatment-naive NSCLC patients with EGFR Exon20ins according to RECIST 1.1 by IRC.\n\nConfirmed ORR was defined as the percentage of patients achieving a CR or PR and was confirmed by subsequent tumor assessment at least 4 weeks within the study period.\n\nConfirmed DCR was defined as the proportion of patients with a best overall response of CR, PR, or SD. Patients who achieved a CR or PR must be confirmed by subsequent tumor assessment at least 4 weeks within the study period.\n\nPatients who achieved a best overall response of SD must be confirmed by subsequent tumor assessment at least 35 days within the study period.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with EGFR exon20ins, treatment naïve. Patients received sunvozertinib 300 mg once daily dosing with a low-fat meal continuously.","id":"OG000","title":"Part A Dose Expansion Cohort 5: Treatment naïve, Sunvozertinib 300 mg, Dosing With a Low-fat Meal"}],"paramType":"NUMBER","populationDescription":"Only participants in Part A were presented here, while Part B were presented separately. According to the clinical study protocol, only participants in Part A Dose Expansion Cohort 5 (treatment-naive patients) were evaluated by IRC. Therefore, we only present the IRC results from Part A Dose Expansion Cohort 5.","reportingStatus":"POSTED","timeFrame":"The study duration was from the initiation of sunvozertinib treatment until the study completion. The median study duration was 10 months, and the maximal study duration was 51.4 months for part A.","title":"Part A: Confirmed ORR and DCR by Independent Review Committee (IRC).","type":"SECONDARY","unitOfMeasure":"percentage of participants"}